Compare · CYPH vs NVO
CYPH vs NVO
Side-by-side comparison of Cypherpunk Technologies Inc. (CYPH) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYPH and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.92B, about 2830.3x CYPH ($69.2M).
- Over the past year, CYPH is up 58.8% and NVO is down 45.1% - CYPH leads by 103.9 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 2 for CYPH).
- NVO has more recent analyst coverage (25 ratings vs 0 for CYPH).
- Company
- Cypherpunk Technologies Inc.
- Novo Nordisk A/S
- Price
- $0.65-4.87%
- $43.88-0.20%
- Market cap
- $69.2M
- $195.92B
- 1M return
- -37.23%
- -6.80%
- 1Y return
- +58.83%
- -45.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CYPH
- SEC Form S-8 filed by Cypherpunk Technologies Inc.
- SEC Form 8-K filed by Cypherpunk Technologies Inc.
- Cypherpunk Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cypherpunk Technologies Reports First Quarter 2026 Financial Results
- SEC Form 10-Q filed by Cypherpunk Technologies Inc.
- SEC Form DEFA14A filed by Cypherpunk Technologies Inc.
- SEC Form DEF 14A filed by Cypherpunk Technologies Inc.
- Cypherpunk Increases its Zcash Stake, Launches New Website and Investor Dashboard
- Cypherpunk Technologies Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 4 filed by Mirabelli Christopher
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care